Tazverik Receives Accelerated Approval for Follicular LymphomaThe United States Food and Drug Administration (US FDA) has approved Tazverik for use in relapsed or refractory (R/R) follicular lymphoma. Tazverik (tazemetostat) is for adults with a mutation in... By Editorial Team2 min readBookmark for later Reactions 0 reactions Comments1 comments
FDA Approves Darzalex Faspro For Multiple MyelomaThe United States Food and Drug Administration (US FDA) has approved Darzalex Faspro for the treatment of newly diagnosed or relapsed/refractory multiple myeloma. Darzalex Faspro (a combination of the drugs... By Editorial Team3 min readBookmark for later Reactions 0 reactions Comments0 comments
FDA Approves Ibrutinib plus Rituximab for Chronic Lymphocytic LeukemiaThe U.S. Food and Drug Administration (FDA) has granted approval to the Janssen Pharmaceutical Companies of Johnson & Johnson to expand the indications for Imbruvica® (ibrutinib) to be used in... By Editorial Team2 min readBookmark for later Reactions 0 reactions Comments1 comments
What to Know About Cancer and COVID-19 (Coronavirus)The spread of the novel coronavirus, COVID-19, has changed our daily lives. But people with a higher risk for illness from COVID-19 are wondering what they can do to stay... By Editorial Team4 min readBookmark for later Reactions 0 reactions Comments1 comments
Take the Fatigue and Health Survey!The 2020 Fatigue and Health survey has now closed. Thank you for your interest! We are excited to share the results with you soon.Exhaustion, tiredness, weariness... fatigue. We know chronic... By Editorial Team1 min readBookmark for later Reactions 0 reactions Comments2 comments
FDA Makes Way for Experimental Drugs to Fight COVID-19On March 19, the U.S. Food and Drug Administration (FDA) approved the testing of two drugs, chloroquine (hydroxychloroquine) and remdesivir, to treat people with COVID-19. The drugs have been given... By Editorial Team3 min readBookmark for later Reactions 0 reactions Comments1 comments
COVID-19: Tips To Reduce Your RiskWith all of the news circulating about the novel (new) coronavirus, it can be easy to feel overwhelmed or anxious. This is especially true if you are immune-compromised due to... By Editorial Team4 min readBookmark for later Reactions 0 reactions Comments2 comments
COVID-19: Basics for the Immune-CompromisedFor those living with chronic health conditions, current news about the coronavirus (COVID-19) can be anxiety-inducing. We have questions and concerns about how the virus is transmitted, how it can... By Editorial Team5 min readBookmark for later Reactions 0 reactions Comments4 comments
FDA Approves Sarclisa® for Previously Treated Multiple MyelomaThe U.S. Food and Drug Administration (FDA) has granted approval to Sanofi-Aventis U.S. LLC for Sarclisa® (isatuximab-irfc), to be used in combination with pomalidomide and dexamethasone for the treatment of... By Editorial Team3 min readBookmark for later Reactions 0 reactions Comments1 comments
The American Cancer Society Issues 2020 Report on CancerThe American Cancer Society (ACS) recently released its report, Cancer Statistics, 2020. The report found that the death rate from cancer in the US is dropping. Between 1991 and 2017... By Editorial Team3 min readBookmark for later Reactions 0 reactions Comments1 comments
FDA Approves Calquence for CLL and SLLThe drug acalabrutinib (Calquence®) was recently approved to treat 2 more types of blood cancer in adults: chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL). It had already been... By Editorial Team2 min readBookmark for later Reactions 0 reactions Comments1 comments
FDA Approves Brukinsa for Treatment of Mantle Cell LymphomaRecently, the U.S. Food and Drug Administration (FDA) approved BrukinsaTM (zanubrutinib) to treat mantle cell lymphoma. Mantle cell lymphoma is a rare type of non-Hodgkin lymphoma (NHL), a blood cancer... By Editorial Team3 min readBookmark for later Reactions 0 reactions Comments1 comments
FDA Approves Darzalex Combination for Newly Diagnosed, Stem Cell Transplant-Eligible Multiple MyelomaThis past week, the United States Food and Drug Administration (U.S. FDA) approved the monoclonal antibody daratumumab (Darzalex) for the treatment of adults with newly diagnosed multiple myeloma who are... By Editorial Team2 min readBookmark for later Reactions 0 reactions Comments2 comments
Take the Chronic Pain In America Survey! (Now Closed)We know the frustrations of chronic pain. Will you help others understand by taking our survey? Simply put, living with chronic pain is painful. But there is so much more... By Editorial Team1 min readBookmark for later Reactions 0 reactions Comments2 comments
New Study Shows Family History of Blood Cancer Increases RiskAlthough the risks for developing blood cancer are still being researched and not fully known or understood, there may be a genetic component to it. A combination of genetic and... By Editorial Team3 min readBookmark for later Reactions 0 reactions Comments3 comments
FDA Approves Inrebic for MyelofibrosisMyelofibrosis, a rare bone marrow disorder, is a chronic disorder in which scar tissue forms in the bone marrow. This forces production of blood cells from the bone marrow to... By Editorial Team2 min readBookmark for later Reactions 0 reactions Comments2 comments
FDA Approves Ruxience, a Rituxan BiosimilarIn July 2019, the United States Food and Drug Administration (FDA) approved Ruxience™, a new Rituxan biosimilar. Ruxience (rituximab-pvvr), was approved for the use in CD-20 positive, B-cell, non-Hodgkin lymphoma... By Editorial Team1 min readBookmark for later Reactions 0 reactions Comments1 comments
FDA Approves Xpovio for Relapsed/Refactory Multiple MyelomaThe U.S. Food and Drug Administration (FDA) has granted accelerated approval to Xpovio (selinexor, Karyopharm Therapeutics) a combination treatment for adults with relapsed/refractory multiple myeloma (RRMM) who have received at... By Editorial Team3 min readBookmark for later Reactions 0 reactions Comments1 comments
Project Facilitate to Increase Access to Compassionate Use TreatmentsFor some battling cancer, especially those with more advanced or aggressive cancers, approved or available treatment options may eventually become limited. When this happens, some may turn to clinical trials... By Editorial Team2 min readBookmark for later Reactions 0 reactions Comments3 comments
FDA Approves New Combination Therapy for Follicular Lymphoma and Marginal Zone LymphomaThe U.S. Food and Drug Administration (FDA) recently approved Revlimid® (lenalidomide) in combination with Rituxan® (rituximab) for the treatment of previously treated follicular lymphoma and marginal zone lymphoma. This combination... By Pamela Munnelly1 min readBookmark for later Reactions 0 reactions Comments2 comments
